Arcutis Biotherapeutics, Inc.
ARQTNASDAQHealthcare● Active
$21.54
+$0.31(+1.46%)
Market Cap$2.7B
P/E Ratio—
52W High$31.77
52W Low$12.72
Arcutis Biotherapeutics, Inc. (ARQT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARQT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.09
Est. -$0.02 · -350.0%
Revenue
$0.11B
Est. $0.10B · +1.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ARQT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.04 | — | — | — | $0.12B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.02 | -$0.09 | -350.0% | $0.11B | $0.10B | +1.7% |
| ▲ Q1 FY2026 | Feb 25, 2026 | $0.03 | $0.13 | +333.3% | $0.13B | $0.11B | +14.6% |
| ▲ Q4 FY2025 | Oct 28, 2025 | -$0.10 | $0.06 | +160.0% | $0.10B | $0.11B | -10.4% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.18 | -$0.13 | +27.8% | $0.08B | $0.08B | +1.1% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.21 | -$0.20 | +4.8% | $0.07B | $0.07B | -9.4% |
| ▲ Q1 FY2025 | Feb 25, 2025 | -$0.28 | -$0.09 | +67.9% | $0.07B | $0.06B | +17.9% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.42 | -$0.33 | +21.4% | $0.04B | $0.04B | +19.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.02
EPS Surpr.
-350.0%
Revenue
$0.11B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
$0.13
EPS Est.
$0.03
EPS Surpr.
+333.3%
Revenue
$0.13B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$0.06
EPS Est.
-$0.10
EPS Surpr.
+160.0%
Revenue
$0.10B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.18
EPS Surpr.
+27.8%
Revenue
$0.08B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.21
EPS Surpr.
+4.8%
Revenue
$0.07B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
-$0.09
EPS Est.
-$0.28
EPS Surpr.
+67.9%
Revenue
$0.07B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.33
EPS Est.
-$0.42
EPS Surpr.
+21.4%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.29 | $0.29 | $0.30 | 2 |
| Q3 FY2027 | $0.19 | $0.20 | $0.21 | 1 |
| Q2 FY2027 | $0.13 | $0.14 | $0.14 | 1 |
| Q1 FY2027 | $0.08 | $0.08 | $0.08 | 2 |
| Q4 FY2026 | $0.14 | $0.15 | $0.15 | 2 |
| Q3 FY2026 | $0.05 | $0.08 | $0.14 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.1B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -350.0% | $23.42 | $24.17 | +3.20% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +333.3% | $26.98 | $27.01 | +0.11% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +160.0% | $19.64 | $24.95 | +27.04% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +27.8% | $15.33 | $15.36 | +0.20% |
| ▲ Q2 FY2025 | May 6, 2025 | +4.8% | $15.41 | $14.32 | -7.07% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +67.9% | $12.39 | $12.20 | -1.53% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +21.4% | $9.30 | $9.66 | +3.87% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +12.5% | $9.95 | $9.58 | -3.72% |
Q2 FY2026+3.20%
Report Date
May 6, 2026
EPS Beat/Miss
-350.0%
Price Before
$23.42
Price After
$24.17
Q1 FY2026+0.11%
Report Date
Feb 25, 2026
EPS Beat/Miss
+333.3%
Price Before
$26.98
Price After
$27.01
Q4 FY2025+27.04%
Report Date
Oct 28, 2025
EPS Beat/Miss
+160.0%
Price Before
$19.64
Price After
$24.95
Q3 FY2025+0.20%
Report Date
Aug 6, 2025
EPS Beat/Miss
+27.8%
Price Before
$15.33
Price After
$15.36
Q2 FY2025-7.07%
Report Date
May 6, 2025
EPS Beat/Miss
+4.8%
Price Before
$15.41
Price After
$14.32
Q1 FY2025-1.53%
Report Date
Feb 25, 2025
EPS Beat/Miss
+67.9%
Price Before
$12.39
Price After
$12.20
Q4 FY2024+3.87%
Report Date
Nov 6, 2024
EPS Beat/Miss
+21.4%
Price Before
$9.30
Price After
$9.66
Q3 FY2024-3.72%
Report Date
Aug 14, 2024
EPS Beat/Miss
+12.5%
Price Before
$9.95
Price After
$9.58
Avg Beat Reaction+2.70%
Avg Miss Reaction+3.20%
Beat Rate7 / 8 quarters
Largest Move+27.04% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARQT ends December
Arcutis Biotherapeutics, Inc. (ARQT) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.09 — missing the analyst consensus of $-0.02 by -350.0%. The next ARQT earnings date is expected around September 1, 2026.
Each quarter, investors track ARQT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARQT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARQT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARQT earnings · 5 questionsArcutis Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. ARQT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARQT historically reports after market close (AMC).
ARQT earnings datewhen is ARQT earningsARQT next earnings datewhen does ARQT report earningsARQT earnings calendar
▸ Source: FMP · Arcutis Biotherapeutics, Inc. SEC filings · US GAAP · Arcutis Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026